Protagonist Therapeutics, Inc. (PTGX) Financials

PTGX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 358.0 million 21.3 million
2023-09-30 330.0 million 27.9 million
2023-06-30 320.5 million 26.4 million
2023-03-31 239.9 million 23.7 million

PTGX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 16.9 million 6.6 million
2023-09-30 -27.0 million 6.8 million
2023-06-30 -26.4 million 8.3 million
2023-03-31 -34.4 million 7.6 million

PTGX Net Income

No data available :(

PTGX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 341.6 million - 1.1 million
2023-09-30 322.7 million - 1.8 million
2023-06-30 313.4 million - 2.4 million
2023-03-31 230.8 million - 3.1 million

PTGX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 61.8 million
2023-09-30 59.2 million
2023-06-30 56.8 million
2023-03-31 50.6 million

PTGX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 19000 28.9 million 8.1 million -
2023-09-30 404000 30.7 million 7.7 million -
2023-06-30 176000 33.2 million 9.2 million -
2023-03-31 10000 27.4 million 8.6 million -

PTGX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 60.0 million 832000
2023-09-30 - 827000
2023-06-30 - 821000
2023-03-31 - 832000

PTGX

Price: $25.54

52 week price:
13.72
33.34

Earnings Per Share: -1.39 USD

P/E Ratio: -9.97

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 966400

Ebitda: -4.9 million

Market Capitalization: 1.6 billion

Links: